Neurodegenerative Diseases

213 Pages·2010·3.018 MB·English

by  Roland W. Bürli, Elizabeth Thomas, Vahri Beaumont (auth.), Celia Dominguez (eds.)

6
Topics in Medicinal Chemistry
Editorial Board:
P. R.Bernstein ·A. Buschauer ·G.J. Georg ·J. A.Lowe ·H.U.Stilz
.
Neurodegenerative Diseases
Volume Editor: Celia Dominguez
With contributions by
R.W.Bu¨rli(cid:1)K.R.Bales(cid:1)V.Beaumont(cid:1)S.Courtney(cid:1)A.Duplantier(cid:1)
M. E. Gurney (cid:1) A. S. Kiselyov (cid:1) I. Mun˜oz-Sanjuan (cid:1) F. S. Menniti (cid:1)
(cid:1) (cid:1) (cid:1) (cid:1)
N. Plath E. Schaeffer A. Scheel N. Svenstrup E. Thomas
Editor
Dr.CeliaDominguez
CHDIManagementInc.
Advisorsto
CHDIFoundation,Inc.
CenterDrive6080
90045LosAngelesCalifornia
Suite100
USA
[email protected]
ISSN1862-2461 e-ISSN1862-247X
ISBN978-3-642-16757-7 e-ISBN978-3-642-16758-4
DOI10.1007/978-3-642-16758-4
SpringerHeidelbergDordrechtLondonNewYork
#Springer-VerlagBerlinHeidelberg2010
Thisworkissubjecttocopyright.Allrightsarereserved,whetherthewholeorpartofthematerialis
concerned,specificallytherightsoftranslation,reprinting,reuseofillustrations,recitation,broad-
casting,reproductiononmicrofilmorinanyotherway,andstorageindatabanks.Duplicationofthis
publicationorpartsthereofispermittedonlyundertheprovisionsoftheGermanCopyrightLawof
September 9, 1965, in its current version, and permission for use must always be obtained from
Springer.ViolationsareliabletoprosecutionundertheGermanCopyrightLaw.
Theuseofgeneraldescriptivenames,registerednames,trademarks,etc.inthispublicationdoesnot
imply,evenintheabsenceofaspecificstatement,thatsuchnamesareexemptfromtherelevant
protectivelawsandregulationsandthereforefreeforgeneraluse.
Coverdesign:Ku¨nkelLopkaGmbH,Heidelberg,Germany
TypesettingandProduction:SPiPublisherServices
SpringerispartofSpringerScienceþBusinessMedia(www.springer.com)
Volume Editor
Dr.CeliaDominguez
CHDIManagementInc.
Advisorsto
CHDIFoundation,Inc.
CenterDrive6080
90045LosAngelesCalifornia
Suite100
USA
[email protected]
Editorial Board
Dr.PeterR.Bernstein JohnA.Lowe
AstraZenecaPharmaceuticals [email protected]
1800ConcordPike
FairfaxResearchCenterB313 Dr.HansUlrichStilz
POBox15437
AventisPharmaDeutschlandGmbH
Wilmington,DE19850-5437
Geb.G838
USA
65926Frankfurta.M.
Germany
Prof.Dr.ArminBuschauer
InstituteofPharmacy
UniversityofRegensburg
Universita¨tsstr.31
93053Regensburg
Germany
Prof.Dr.GundaJ.Georg
UniversityofMinnesota
DepartmentofMedicalChemistry
8-101AWeaverDensfordHall
Minneapolis,MN55455
USA
v
.
Topics in Medicinal Chemistry
Also Available Electronically
Topics in Medicinal Chemistry is included in Springer’s eBook package
Chemistry and Materials Science. If a library does not opt for the whole
package the book series may be bought on a subscription basis. Also, all
backvolumesareavailableelectronically.
ForallcustomerswhohaveastandingordertotheprintversionofTopics
inMedicinalChemistry,weoffertheelectronicversionviaSpringerLinkfree
ofcharge.
If you do not have access, you can still view the table of contents of each
volume and the abstract of each article by going to the SpringerLink home-
page, clicking on “Browse by Online Libraries”, then “Chemical Sciences,”
andfinallybyselectingTopicsinMedicinalChemistry.
Youwillfindinformationaboutthe
–EditorialBoard
–AimsandScope
–InstructionsforAuthors
–SampleContribution
at springer.com using the search function by typing in Topics in Medicinal
Chemistry.
Color figures are published in full color in the electronic version on
SpringerLink.
Aims and Scope
Drug research requires interdisciplinary team-work at the interface between
chemistry, biology and medicine. Therefore, the new topic-related series
Topics in Medicinal Chemistry will cover all relevant aspects of drug
research, e.g. pathobiochemistry of diseases, identification and validation
of (emerging) drug targets, structural biology, drugability of targets, drug
designapproaches,chemogenomics,syntheticchemistryincludingcombina-
torial methods, bioorganic chemistry, natural compounds, high-throughput
screening, pharmacological in vitro and in vivo investigations, drug-
receptorinteractionsonthe molecularlevel,structure-activity relationships,
drug absorption, distribution, metabolism, elimination, toxicology and
pharmacogenomics.
Ingeneral,specialvolumesareeditedbywellknownguesteditors.
InreferencesTopicsinMedicinalChemistryisabbreviatedTopMedChem
andiscitedasajournal.
vii
.
Preface to the Series
Medicinalchemistryisbothscienceandart.Thescienceofmedicinalchem-
istry offers mankind one of its best hopes for improving the quality of life.
The art of medicinal chemistry continues to challenge its practitioners with
the need for both intuition and experience to discover new drugs. Hence
sharingtheexperienceofdrugdiscoveryisuniquelybeneficialtothefieldof
medicinalchemistry.
TheseriesTopicsinMedicinalChemistryisdesignedtohelpbothnovice
and experienced medicinal chemists share insights from the drug discovery
process. For the novice, the introductory chapter to each volume provides
background and valuable perspective on a field of medicinal chemistry not
availableelsewhere.Succeedingchaptersthenprovideexamplesofsuccessful
drugdiscoveryeffortsthatdescribethemostup-to-dateworkfromthisfield.
Theeditorshavechosentopicsfrombothimportanttherapeuticareasand
fromworkthatadvancesthedisciplineofmedicinalchemistry.Forexample,
cancer, metabolic syndrome and Alzheimer’s disease are fields in which
academia and industry are heavily invested to discover new drugs because
of their considerable unmet medical need. The editors have therefore prior-
itized covering new developments in medicinal chemistry in these fields. In
addition,importantadvancesinthediscipline,suchasfragment-baseddrug
designandotheraspectsofnewlead-seekingapproaches,arealsoplannedfor
earlyvolumesinthisseries.Eachvolumethusoffersauniqueopportunityto
capturethemostup-to-dateperspectiveinanareaofmedicinalchemistry.
Dr.PeterR.Bernstein
Prof.Dr.ArminBuschauer
Prof.Dr.GundaJ.Georg
Dr.JohnLowe
Dr.HansUlrichStilz
ix